In 2025, the Egyptian Drug Authority (EDA) published a dedicated regulatory guideline outlining the procedures for registering and obtaining import approvals in Egypt for medical devices, in-vitro diagnostics (IVDs), and laboratory equipment that are marketed in Great Britain (England, Wales, and Scotland) under UKCA conformity but not marketed in the European Union. This guideline creates a structured pathway for companies holding UK Conformity Assessed (UKCA) markings to enter the Egyptian medical device market.

What Is UKCA and Why Does It Matter for Egyptian Import?

The UK Conformity Assessed (UKCA) mark is the product conformity mark used in Great Britain (distinct from the EU’s CE mark) to indicate that a device meets the United Kingdom’s product safety and regulatory requirements. While UKCA certification enables market access in Great Britain, it has different legal recognition from EU certification. Companies exporting UKCA-only certified devices to other regions therefore need clear regulatory pathways to enter markets like Egypt.

The purpose of the EDA guideline is to ensure that medical devices with UKCA conformity — even without EU certification — can be lawfully imported and registered in Egypt, provided they meet appropriate data, safety, and quality conditions.

Scope of the Guideline

The guidelines apply to:

• Medical devices marketed in Great Britain under UKCA conformity.
• Medical and laboratory equipment also using UKCA certification.
• In-vitro diagnostics (IVDs) that hold UKCA approval but do not carry EU CE marks.

It excludes other conformity schemes and devices that are already marketed in the European Union with CE certification.

Key Elements of the UKCA-Based Registration Process

1. Regulatory Import & Registration Route
   The guideline outlines the regulatory mechanism that companies must follow to register and import UKCA-approved devices into Egypt. While the full procedural steps are detailed in the guideline document itself, the core expectations include:
   • Submission through the EDA’s online platform for import approval and registration applications.
   • Demonstration of product conformity and safety based on UKCA certification documentation.
   • Provision of technical dossiers and supporting data aligned with EDA requirements for device quality and performance.

This mechanism helps bridge regulatory recognition from Great Britain to Egyptian requirements, ensuring that UKCA-certified devices can be considered for market entry even without EU CE compliance.

Why This Guideline Is Important

1. Market Access Flexibility:
   It introduces regulatory flexibility for manufacturers who have invested in UKCA certification — enabling them to enter the Egyptian market without duplicating conformity pathways required under EU routes.
2. Alignment with International Regulatory Diversity:
   By accommodating UKCA conformity, the EDA recognizes global shifts following Brexit and evolving regulatory landscapes, acknowledging that major quality systems exist outside the EU.
3. Predictable Regulatory Path:
   This guideline creates a predictable pathway with defined expectations for documentation and conformity evidence — reducing procedural uncertainty for companies seeking entry into Egypt with non-EU certified devices.

Implications for Manufacturers and Importers

Manufacturers and importers targeting Egypt with UKCA-certified products should prepare to:

• Compile comprehensive technical dossiers supporting safety and performance claims.
• Ensure conformity documentation aligns with both UKCA and EDA expectations.
• Establish clear channels for communication with the EDA during the import and registration process.

Conclusion

The EDA Regulatory Guideline on UKCA Device Registration (Version 2-1, 2025) represents a significant adaptation in Egyptian medical device regulation, enabling UKCA-based conformity to be used as a regulatory basis for importing and registering devices in the Egyptian market. This enhances market access for devices certified under the UK system, facilitating broader availability of healthcare technologies while maintaining patient safety and regulatory oversight.